The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...
The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to ...
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a ...
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded ...
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results